GLUT2 is mainly expressed in the liver, ␤-cells of the pancreas, and the basolateral membrane of kidney proximal tubules and plays an important role in glucose homeostasis in living organisms. The transcription of the GLUT2 gene is known to be upregulated in the liver during postprandial hyperglycemic states or in type 2 diabetes. However, a molecular mechanism by which glucose activates GLUT2 gene expression is not known. In this study, we report evidence that sterol response element-binding protein ( 
A dipocyte determination and differentiation-dependent factor 1 (ADD1)/sterol response element binding protein (SREBP)-1c is a transacting factor that regulates transcription of many genes involved in cholesterol and fatty acid synthesis (1) (2) (3) (4) (5) (6) . To date, three isoforms of SREBP have been identified. SREBP-1a and -1c are derived from a single gene and use different transcription initiation sites (7) . SREBP-2 is transcribed from a separate gene (8) and shows 50% sequence homology to the SREBP-1c isoform. SREBP-2 plays a critical role in the regulation of genes of cholesterol biosynthesis, whereas SREBP-1c regulates lipogenesis genes in liver (9) .
The relative contribution of insulin (10 -14) or glucose (15) (16) (17) to the regulation of specific genes is known to be different. In nonfasted mice, the level of SREBP-1c transcripts in the liver is considerably more abundant than the SREBP-1a transcripts (3) . Fasting decreases the amount of SREBP-1c transcripts by 60%, and refeeding increases the level by 3.8-fold (3) . In contrast, the fasting/refeeding protocol causes only minor changes in the amount of SREBP-1a transcripts (18) . In insulin-resistant animals, such as ob/ob mice, where insulin signaling is known to be impaired (19) , or in other insulin signaling system knockout animals (20) , overexpression of SREBP-1c in the liver was reported (12) . These reports suggested that SREBP-1c induction could also occur by glucose.
The facilitative GLUTs are a group of highly related membrane proteins that share significant sequence homology between isoforms (21) . GLUT2 is known to transport glucose across the hepatic plasma membrane in a bidirectional manner (22, 23) . GLUT2 was upregulated by glucose, like pyruvate kinase and fatty acid synthase (24) . In diabetic states, GLUT2 in the liver and basolateral membrane of renal proximal tubules is known to be upregulated, indicating that hyperglycemia may play a positive role in its gene regulation (25) . And in streptozotocin-induced diabetic rats, where insulin was depleted in vivo (10), SREBP-1c expression was increased in liver. These data lead us to postulate that GLUT2 upregulation in the liver could be due to the activation of the gene by SREBP-1c.
From this background, we have attempted to identify the SREBP-1c response element (SRE) in the promoter region of GLUT2 and demonstrate that glucose increases the binding of SREBP-1c on the GLUT2 promoter, resulting in the activation of GLUT2 transcription.
followed by a melting program, which started at 45°C for 15 s and then increased to 95°C by 0.1°C/s, with the fluorescence signal continuously monitored online . Primers and probes were as follows: GLUT2 sense, 5Ј-GGCTAATTTCAGGACTGGTT-3Ј; GLUT2 antisense, 5Ј-TTTCTTTGCCCTG  ACTTCCT-3Ј; SREBP-1a sense, 5Ј-GGCCGAGATGTGCGAACT-3Ј; SREBP-1a  antisense, 5Ј-TTGTTGATGAGCTGGAGCATGT-3Ј; SREBP-1c sense, 5Ј-GGAG  CCATGGATTGCACATT-3Ј; SREBP-1c antisense, 5Ј-GGCCCGGGAAGTCACT  GT-3Ј; SREBP-2 sense, 5Ј-GCGTTCTGGAGACCATGGA-3Ј; SREBP-2 antisense, 5Ј-CACAAGTTGCTCTGAAAACAAATCA-3Ј ; ␣-tubulin sense, 5Ј-CTCG CATCCACTTCCCTC-3Ј; and ␣-tubulin antisense, 5Ј-ATGCCCTCACCCACGTA C-3Ј. Construction of GLUT2 promoter luciferase plasmids. The GLUT2 promoter fragments of Ϫ1,112/ϩ1 bp were PCR amplified from mouse genomic DNA and subcloned into a pGLM vector and mutated at the E-boxes upstream of the multiple cloning site of the pGL3 basic vector. 5Ј serial deletions of mouse GLUT2 promoter reporter were constructed by amplifying the regions of Ϫ891/ϩ1, Ϫ389/ϩ1, Ϫ286/ϩ1, Ϫ116/ϩ1, and Ϫ57/ϩ1 bp, respectively. SRE mutant construct pmGLUT2d-389m was generated from pmGLUT2d-389 with the mutagenic oligonuleotides (30 mer) using plaque-forming unit polymerase. The sequences of all constructs were confirmed using a T7 sequencing kit (Amersham Biosciences). All transfection plasmids were prepared with the Qiagen Plasmid Midi Kit. Transient transfection assay. Alexander cell lines (American Type Culture Collection number CRL-8024), which are human epithelial hepatoma cell lines, were plated at a density of 2 ϫ 10 5 cells/35-mm dish. On the following day, 0.5 g of each construct of the GLUT2 promoter, 0.1 g of pCMV-␤-galactosidase, with or without 0.1 g of SREBP-1c, and 0.5 g of dominant-negative form of SREBP-1c (SREBP-1c DN) expression vector were mixed. Transient transfection and luciferase assays were performed as described previously (29) . Total protein concentrations of the lysates were determined by the Bradford method (30) . Luciferase activities were normalized by the amount of total protein. Each transfection was performed in triplicate and repeated three to five times. Electrophoretic mobility shift assay. The oligonucleotide probes GLUT2-SRE and GLUT2-SREm (GLUT2-SRE mutant) were labeled as described previously (31) . Ten picomoles of the single-stranded sense oligonucleotide were labeled with [␥-32 P]ATP using T4 polynucleotide kinase and annealed with 50 pmol of unlabeled antisense oligonucleotides. For competition assay, unlabeled oligonucleotides (100-fold molar excess) were added to the reaction mixture. The oligonucleotide sequences used in electrophoretic mobility shift assay (EMSA) were as follows: GLUT2-SRE sense, 5Ј-CCAGGTAGAG TGAGCACTCT-3Ј; GLUT2-SRE antisense, 5Ј-AGAGTGCTCACTCTACCTGG-3Ј; GLUT2-SREm sense, 5Ј-CCAGGTAGAGaacGCACTCT-3Ј; GLUT2-SREm antisense, 5Ј-AGAGTGCgttCTCTACCTGG-3Ј; mLDLR-SRE sense, 5Ј-TTGAAA ATCACCCCATTGCAGACTCCTCCCCGGC-3Ј; and mLDLR-SRE antisense, 5Ј-GCCGGGGAGGAGTCTGCAATGGGGTGATTTTCAA-3Ј. Mutated bases are represented in bold. Preparation of recombinant adenovirus. Recombinant adenovirus encoding SREBP-1c or SREBP-1c DN was prepared according to Choi et al. (32) . Briefly, the respective cDNAs were cloned into pAd-YC2 (5 g) and transfected into 293 cells with a rescue vector, pJM17 (5 g), which is necessary for homologous recombination of the recombinant adenovirus. After 12-15 days, recombinants were screened by PCR using upstream primers derived from the cytomegalovirus promoter and downstream primers from the bGHp(A) sequence. The recombinants were amplified in 293 cells and purified and isolated using CsCl 2 (Sigma). The recombinant adenoviruses were collected and desalted, and titers were determined by the measurement of plaque counts. Treatment of recombinant adenovirus. Null, adenovirus, or adenovirus containing SREBP-1 or SREBP-1c DN were treated according to the method described by Kim et al. (29) . The primary hepatocytes were incubated for 2 h with an adenovirus containing DMEM at a titer of 5 pfu per cell for 2 h at 37°C. Culture medium was then replaced by DMEM supplemented with 10% FBS. The infected cells were harvested for RNA isolation 24 h after viral infection. Chromatin immunoprecipitation assay. The chromatin immunoprecipitation (ChIP) assay protocol was adapted from methods described by Duong et al. (32) . The primary hepatocytes were fasted in fasting medium composed of 2 mmol/l glutamine, 1 mmol/l sodium pyruvate, 10 mmol/l lactate, 10 nmol/l dexamethasone, and 2% FBS for 16 h. The medium was then changed to one containing 25 mmol/l glucose and/or 100 nmol/l insulin for 24 h. Cells were washed with ice-cold PBS and cross-linked with 5% formaldehyde in serumfree DMEM for 5 min. The cells were homogenized, pelleted by centrifugation at 2,000 rpm for 4 min at 4°C, and resuspended in SDS lysis buffer (1% SDS, 10 mmol/l EDTA, 50 mmol/l Tris-HCl, pH 8.0). The lysate was sonicated on ice for 3 min at a setting of cycle 0.5, amplitude 30, and sheared to between 100 and 600 bps. To provide a positive control (input) for each condition, one undiluted aliquot was retained for further processing in parallel with all the
S.-S. IM AND ASSOCIATES

DIABETES, VOL. 54, JUNE 2005
other samples at the reversal of the cross-linking step. To reduce nonspecific background, each chromatin sample (1 ml) was precleared with 60 l of protein A/G agarose (Santa Cruz Biotech), supplemented with 200 g/ml sonicated salmon sperm DNA (Stratagene, La Jolla, CA), and the beads were pelleted. Chromatin complexes in the supernatant were immunoprecipitated overnight at 4°C using either 30 g of SREBP-1 antibody or without antibody. Immune complexes were collected with 60 l of protein A/G agarose including 200 g/ml of salmon sperm DNA (Stratagene). Promoter-specific PCR GLUT2 promoter primers were as follows: sense, 5Ј-CCATCAATACTCAGCTTCTG-3Ј; antisense, 5Ј-TGTGTGTGTGTGGAATTGTC-3Ј. Statistical analysis. All transfection studies were performed in three to five separate experiments, where triplicate dishes were transfected. The data were represented as a mean Ϯ SD. Statistical significance was determined by independent two-sample t tests or paired t tests between two groups of datasets.
RESULTS
Effect of glucose and insulin on the mRNA level of GLUT2 and SREBPs in primary cultured hepatocytes.
To observe the effects of glucose and/or insulin on the expression of SREBP-1 and GLUT2, we treated primary cultured hepatocytes with high glucose (25 mmol/l), insulin (100 nmol/l), or both. Northern blot and real-time PCR analyses showed that treatment with insulin (100 nmol/l) or glucose (25 mmol/l) increased the SREBP-1 mRNA level ( Fig. 1A and B) . However, GLUT2 expression was not affected by insulin alone but was stimulated by addition of high glucose (Fig. 1B , *P Ͻ 0.001 for the untreated vs. glucose-treated group). These data suggest that glucose is a major determinant in GLUT2 gene upregulation. Realtime PCR of the SREBP-1 isoform revealed that insulin or glucose treatment activated SREBP-1c expression (Fig.  1C) , whereas SREBP-1a and SREBP-2 expressions were not affected by both insulin and glucose ( Fig. 1D and E) . Insulin and glucose increased SREBP-1c mRNA level by seven-and fourfold, respectively (Fig. 1C , *P Ͻ 0.005 for the untreated vs. insulin-treated group and #P Ͻ 0.05 for the untreated vs. glucose-treated group). Insulin and glucose showed additive effect (Fig. 1C , †P Ͻ 0.001 for the untreated vs. glucose/insulin-treated group) in activating SREBP-1c expression. Effect of SREBP isoforms on GLUT2 promoter reporter activity in the Alexander cell lines. As shown in Fig. 2 , SREBP-1c activated GLUT2 promoter reporter by 5.2-fold (*P Ͻ 0.001 for the untransfected vs. SREBP-1c group), whereas SREBP-2 activated the promoter by 2.4-fold (#P Ͻ 0.05 for the untransfected vs. SREBP-2 group), suggesting that SREBP-1c acts as more potent activator of GLUT2 promoter than SREBP-2 isoform. Localization and characterization of SRE in the GLUT2 promoter. To identify a putative SRE in the mouse GLUT2 promoter, serial deletion constructs of the 5Ј-flanking region of the GLUT2 promoter were prepared (from Ϫ1,112, Ϫ890, Ϫ389, Ϫ283, Ϫ166, and Ϫ57 to ϩ1, shown in Fig. 3A) , and their responsiveness to SREBP-1c in Alexander cell lines was observed. The SREBP-1c effect was decreased by deleting the bases down to Ϫ57 (pmGT2d-57), indicating that a putative SRE could be located between the Ϫ166-and Ϫ57-bp regions (Fig. 3B , *P Ͻ 0.005 for the Ϫ166-vs. Ϫ57-bp deletion construct). A consensus sequence search suggested that a highly conserved SREBP-1 binding site could be present in this 
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region. To identify an SRE in this region, EMSA was performed. Recombinant SREBP-1 (5) bound well with the probe in a dose-dependent manner up to 60 ng (Fig. 3C) . The specificity of the SREBP-1c binding was further confirmed by the SRE consensus sequence from the LDL receptor (LDLR) promoter (33) (Fig. 3D, lane 3) . Mutation introduced at Ϫ78/Ϫ76 (TGA 3 aac, SRE mutant in Fig.  3D ) resulted in a loss of SREBP-1 binding (Fig. 3D, lanes 5  and 6) . The aac mutant lost its ability to compete the binding of SREBP-1 to the GLUT2-SRE consensus sequence (Fig. 3D, lane 4) . Transfection of the putative GLUT2-SRE mutant promoter construct (pmGT2d-389m) lost its responsiveness to SREBP-1c (Fig. 3E, f) . These results indicate that the Ϫ84/Ϫ76 region acts as a possible SRE regulating GLUT2 gene expression. Effect of a GLUT2-SRE mutation on the glucosestimulated GLUT2 promoter reporter activity. To confirm that the Ϫ84/Ϫ76 region is a functional SRE in the GLUT2 promoter, the GLUT2 promoter reporters (pmGT2d-389 and pmGT2d-389m) were transfected to Alexander cell lines maintained at concentrations of 5 and 25 mmol/l glucose. The wild-type promoter reporter activity was increased by glucose in a dose-dependent manner (Fig. 4A , *P Ͻ 0.05 for the 0 vs. 25 mmol/l glucose-treated group). The GLUT2-SRE mutant construct (pmGT22d-389m) showed decreased promoter reporter activity when compared with wild-type promoter (pmGT22d-389, #P Ͻ 0.05 for the wildversus mutant-type at 25 mmol/l glucose). Again, the activation of the promoter construct by glucose (25 mmol/l) was suppressed by cotransfection of the SREBP-1c DN (Fig. 4B , #P Ͻ 0.05 for the 25 mmol/l vs. 25 mmol/l glucose plus SREBP-1c DN group), indicating that GLUT2 promoter activation by glucose is specifically mediated by SREBP-1c. Glucose-stimulation of GLUT2 gene expression. To observe the effect of glucose on GLUT2 and SREBP-1c mRNA and protein level, primary hepatocytes were maintained at the indicated concentration of glucose. As shown in Fig. 5A and B, GLUT2 mRNA and protein level increased with glucose concentration in a dose-dependent manner. To confirm that SREBP-1c mediates glucose-stimulated GLUT2 expression, we transduced adenovirus containing SREBP-1c DN into the primary hepatocytes in the presence or absence of glucose. Real-time PCR (Fig. 5C, upper  panel) and RT-PCR (Fig. 5C, lower panel) revealed that GLUT2 expression was increased by glucose (25 mmol/l, *P Ͻ 0.005 for the untreated versus glucose-treated group), and the stimulatory effect was suppressed by SREBP-1c DN at the 25-mmol/l glucose concentration (#P Ͻ 0.05 for the glucose-treated versus glucose plus SREBP-1c DN group). These data indicate that SREBP-1c is responsible for the glucose-stimulated GLUT2 gene expression. Glucose increased the binding of SREBP-1 to the GLUT2 promoter in mouse primary cultured hepatocytes. To confirm the binding of SREBP-1 to the GLUT2 promoter by glucose in primary cultured hepatocytes, a ChIP assay was performed. Chromosomal DNA from primary cultured hepatocytes was cross-linked using formaldehyde, and an antibody specific to SREBP-1 was used to immunoprecipitate the chromatin fragment. A specific region of the GLUT2 promoter (Ϫ84/Ϫ76) was amplified by PCR. The binding of SREBP-1 to the GLUT2 promoter was increased by glucose or glucose/insulin treatment (Fig. 6A) . The SREBP-1 binding to the GLUT2 promoter was increased in a dose-dependent manner (Fig. 6B) . However, insulin did not affect the binding of SREBP-1 to the putative SRE. These results indicate that glucose could be one of the major factors in the binding of SREBP-1 to the GLUT2 promoter, which may help explain the upregulation of GLUT2 gene expression by glucose.
DISCUSSION
Recently, it has been suggested that the carbohydrateresponsive element-binding protein (ChREBP) plays a pivotal role in glucose-regulated gene expression (34) , whereas SREBP-1c acts as a major mediator of insulin action in the lipogenic genes or in hepatic glucokinase (35, 36) and lipogenic gene expression (9, 37) . However, glucose is required for lipogenic gene induction, where insulin only plays a permissive role (15) (16) (17) . In insulinresistant animals in which insulin signaling is impaired, SREBP-1c expression in liver was shown to be increased. For example, upregulation of SREBP-1c was reported in the leptin-deficient obese ob/ob mice, lipoatrophic mice overexpressing SREBP-1c in adipose tissue (19) , insulin receptor substrate-2 knockout mice (20) , and rat primary hepatocytes infected with adenovirus-overexpressing dominant-negative Akt (12). These observations suggest that there may be additional mechanism of SREBP-1c induction other than insulin signaling.
In this study, we demonstrated that glucose induced the gene expression of SREBP-1c and GLUT2 in a dose-dependent manner in the primary hepatocytes. Furthermore, expression of GLUT2 gene is decreased by adenoviral transduction of SREBP-1c DN in the mouse primary cultured hepatocytes, indicating that glucose-stimulated GLUT2 expression is mediated by SREBP-1c. We have identified a functional SRE in the mouse GLUT2 promoter and demonstrated that SREBP-1c is the transacting factor mediating glucose-stimulated GLUT2 gene expression.
The question of how insulin-induced SREBP-1c did not activate the GLUT2 gene expression, but glucose-induced SREBP-1c increased GLUT2 mRNA level is not currently understood. As shown in Fig. 6A , SREBP-1c induced by insulin did not bind to GLUT2 promoter, whereas SREBP-1c binding to GLUT2 promoter at high glucose concentration was increased. We speculate that this difference in the binding of SREBP-1c to SRE of GLUT2 promoter could be due to 1) difference in the coregulators recruiting SREBP-1c to SRE by insulin or glucose, or 2) sequence specificity of GLUT2-SRE for SREBP-1c mediated by insulin or glucose signaling. Mostly, studies on the 
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phenotypic changes in SREBP-1c knockout mice have been focused on the alteration in the lipid metabolism. On a normal diet, mRNAs encoding enzymes of fatty acid and triglyceride synthesis, including fatty acid synthase and acetyl-CoA carboxylase, are shown to be reduced in the liver of SREBP-1c-deficient mice (3). However, a compensatory increase in hepatic SREBP-2 mRNA, accompanied by increased mRNA level for cholesterol biosynthetic enzymes, was observed (38) . Thus, these mice showed an increase in hepatic cholesterol content. The SREBP-1-deficient mice showed low level of plasma cholesterol and triglycerides (3) . At present, phenotypic changes in SREBP-1c knockout mice with regard to carbohydrate metabolism is not well studied. We assumed that in the insulin-deficient or -resistant state, where SREBP-1c transcription is low and gluconeogenesis is active in liver, the glucose-induced SREBP-1c may play a role in transporting glucose out of hepatocytes into blood, contributing to hyperglycemia. Our studies may provide insight into the understanding of a role of GLUT2 on deranged carbohydrate metabolism in type 2 diabetes. 
